Amber Donahue

Amber Donahue serves as the Director of Biomarker Sciences at IDEAYA Biosciences since May 2023, focusing on biomarker discovery and implementation for IDEAYA's IDE161 PARG inhibitor. Prior to this role, Amber was the Director of Translational Medicine at Instil Bio, working on TIL engineering programs and biomarker initiatives to support clinical trials and regulatory approvals. Amber's experience at Pfizer included roles as Biomarker Clinical Assay Lead-Director and Biomarker Assay Specialist, where contributions were made to translational oncology research. Earlier career highlights include senior scientific roles at Quest Diagnostics, where Amber designed assays for cancer diagnostics, and a research associate position at the University of California-Irvine. Amber earned a Ph.D. in Immunology/Molecular Biology from UC Irvine and a BA in Biology from Grinnell College.